Login Register Cart 0
Review Article

Ferroptosis与肿瘤的关系：一种新的治疗方法

卷 19, 期 2, 2019

页: [117 - 124] 页: 8

弟呕挨: 10.2174/1566523219666190628152137

open access plus

摘要

背景：Ferroptosis是一种新发现的铁依赖性氧化细胞死亡形式，其特征在于基于脂质的活性氧（ROS）的致死累积。它在形态学，生物化学和遗传学方面不同于其他形式的细胞死亡，包括细胞凋亡，坏死和自噬。 讨论：可以通过系统xc-抑制剂或谷胱甘肽过氧化物酶4（GPx4）抑制剂以及诸如索拉非尼，柳氮磺胺吡啶（SAS）和青蒿琥酯（ART）等药物诱导Ferroptosis。 Ferroptosis最近被证明是调节肿瘤生长的关键，如肝细胞癌（HCC），肾细胞癌（RCC），非小细胞肺癌（NSCLC），卵巢癌，胰腺癌和弥漫性大B细胞。淋巴瘤（DLBCL）。 Ferroptosis还与化学治疗药物的抗性和免疫疗法的抗肿瘤功效有关。 结论：本综述总结了铁上睑下垂的机制及其与不同类型肿瘤的关系，以促进我们对细胞死亡的理解，并为临床癌症管理找到一种新方法。

关键词: Ferroptosis，铁代谢，ROS，癌症，化疗药物抗性，治疗方法。

« Previous Next »
图形摘要

[1]
Gao M, Monian P, Jiang X, et al. Metabolism and iron signaling in ferroptotic cell death. Oncotarget 2015; 6(34): 35145-6.
[2]
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149(5): 1060-72.
[3]
Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci 2016; 73(11-12): 2195-209.
[4]
Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3(3): 285-96.
[5]
Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15(3): 234-45.
[6]
Toyokuni S, Ito F, Yamashita K, et al. Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radic Biol Med 2017; 108: 610-26.
[7]
Cramer SL, Saha A, Liu J, Tadi S, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med 2017; 23(1): 120-7.
[8]
Yang WS. SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156(1-2): 317-31.
[9]
Kim SE, Zhang L, Ma K, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol 2016; 11(11): 977-85.
[10]
Yang WS. SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156(1-2): 317-31.
[11]
Sato H, Tamba M, Ishii T, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274(17): 11455-8.
[12]
Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 2012; 42(1): 231-46.
[13]
Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013; 18(5): 522-55.
[14]
Ishii T, Bannai S, Sugita Y, et al. Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. J Biol Chem 1981; 256(23): 12387-92.
[15]
Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 2014; 3e2523
[16]
Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13(5): 342-55.
[17]
Manz DH, Blanchette NL, Paul BT, et al. Iron and cancer: recent insights. Ann N Y Acad Sci 2016; 1368(1): 149-61.
[18]
Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007; 447(7146): 864-8.
[19]
Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 2014; 3e2523
[20]
Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 2015; 34(45): 5617-25.
[21]
Tan S, Schubert D, Maher P, et al. Oxytosis: A novel form of programmed cell death. Curr Top Med Chem 2001; 1(6): 497-506.
[22]
Bridges RJ, Natale NR, Patel SA, et al. System xc (-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol 2012; 165(1): 20-34.
[23]
Mehta A, Prabhakar M, Kumar P, et al. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013; 698(1-3): 6-18.
[24]
Wolpaw AJ, Shimada K, Skouta R, et al. Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci USA 2011; 108(39): E771-80.
[25]
Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15(3): 234-45.
[26]
Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 2013; 1830(5): 3289-303.
[27]
Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014; 16: 1180-91.
[28]
Imai H, Nakagawa Y. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 2003; 34: 145-69.
[29]
Xie Y, Song X, Sun X, et al. Identification of baicalein as a ferroptosis inhi- bitor by natural product library screening. Biochem Biophys Res Commun 2016; 473: 775-80.
[30]
Shintoku R, Takigawa Y, Yamada K, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci 2017; 108: 2187-94.
[31]
Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015; 520(7545): 57-62.
[32]
Liu DS, Duong CP, Haupt S, et al. Inhibiting the system xC (-)/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun 2017; 8: 14844.
[33]
Wang SJ, Li DW, Ou Y, et al. Acetylation is crucial for p53-mediated Ferroptosis and Tumor Suppression. Cell Rep 2016; 17(2): 366-73.
[34]
Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 2015; 59: 298-308.
[35]
Chao Mao, Xiang Wang, Yating Liu, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res 2018; 78(13): 3484-96.
[36]
Min Wang, Chao Mao, Lianlian Ouyang, et al. Long. noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ 2019.
[http://dx.doi.org/10.1038/s41418-019-0304-y]
[37]
Zhang K, Wu L, Zhang P, et al. miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma. Mol Carcinog 2018; 57: 1566-7.
[38]
Wu Y, Sun X, Song B, et al. MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. Cancer Med 2017; 6: 1686-97.
[39]
Drayton RM, Dudziec E, Peter S, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 2014; 20: 1990-2000.
[40]
Liu XX, Li XJ, Zhang B, et al. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett 2011; 585: 1363-7.
[41]
Kabaria S, Choi DC, Chaudhuri AD, et al. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic Biol Med 2015; 89: 548-56.
[42]
Babu KR, Muckenthaler MU. miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) 2016; 94: 347-59.
[43]
Yoshioka Y, Kosaka N, Ochiya T, et al. Micromanaging iron homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem 2012; 287: 34110-9.
[44]
Kindrat I, Tryndyak V, de Conti A, et al. MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget 2016; 7: 1276-87.
[45]
Shpyleva SI, Tryndyak VP, Kovalchuk O, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011; 126: 63-71.
[46]
Andolfo I, De Falco L, Asci R, et al. Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA let-7d in erythroid cells. Haematologica 2010; 95: 1244-52.
[47]
Wu X, Zhi F, Lun W, et al. Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis. Int J Mol Med 2018; 41: 1992-2002.
[48]
Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. PLoS One 2015; 10e0122674
[49]
Kyrychenko S, Kyrychenko V, Badr MA, et al. Pivotal role of miR-448 in the development of ROS-induced cardiomyopathy. Cardiovasc Res 2015; 108: 324-34.
[50]
Hass C, Belz K, Schoeneberger H, et al. Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis. Biochem Pharmacol 2016; 105: 14-22.
[51]
Yu Y, Xie Y, Cao L, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol 2015; 2(4)e1054549
[52]
Hao S, Yu J, He W, et al. Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells. Neoplasia 2017; 19(12): 1022-32.
[53]
Wang SF, Chen MS, Chou YC, et al. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2alpha-ATF4-xCT pathway. Oncotarget 2016; 7(45): 74132-51.
[54]
Ohman KA, Hashim YM, Vangveravong S, et al. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget 2016; 7(23): 33529-41.
[55]
Yamaguchi H, Hsu JL, Chen CT, et al. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin Cancer Res 2013; 19(4): 845-54.
[56]
Roh JL, Kim EH, Jang HJ, et al. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett 2016; 381(1): 96-103.
[57]
Chen L, Li X, Liu L, et al. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-gamma-lyase function. Oncol Rep 2015; 33(3): 1465-74.
[58]
Schott C, Graab U, Cuvelier N, et al. Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death. Front Oncol 2015; 5: 131.
[59]
Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 2013; 133(7): 1732-42.
[60]
Lachaier E, Louandre C, Godin C, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res 2014; 34(11): 6417-22.
[61]
Houessinon A, Francois C, Sauzay C, et al. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol Cancer 2016; 15(1): 38.
[62]
Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016; 64(2): 488-500.
[63]
Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 2016; 63(1): 173-84.
[64]
Bai T, Wang S, Zhao Y, et al. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2017; 491(4): 919-25.
[65]
Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 2015; 356(2 Pt B): 971-7.
[66]
Gout PW, Simms CR, Robertson MC, et al. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 2003; 14(1): 21-9.
[67]
Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001; 15(10): 1633-40.
[68]
Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 2015; 22(11): 1045-54.
[69]
Greenshields AL, Shepherd TG, Hoskin DW, et al. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog 2017; 56(1): 75-93.
[70]
Eling N, Reuter L, Hazin J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015; 2(5): 517-32.
[71]
Zheng DW, Lei Q, Zhu JY, et al. Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy. Nano Lett 2017; 17(1): 284-91.
[72]
Ma S, Dielschneider RF, Henson ES, et al. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One 2017; 12e0182921
[73]
Buccarelli M, Marconi M, Pacioni S, et al. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death Dis 2018; 9: 841.
[74]
Shen Z, Song J, Yung BC, et al. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater 2018; 30e1704007
[75]
Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 2011; 108: 8773-8.
[76]
Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019; 569(7755): 270-4.

Rights & Permissions Print Cite
Article Metrics
154
21
1
© 2024 Bentham Science Publishers | Privacy Policy